Cargando…

T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER

BACKGROUND: Very little is known about the effectiveness of pharmacotherapies for delusional disorders. METHODS: We aimed to study the comparative effectiveness of pharmacological agents for delusional disorder using Swedish national registries to observe a national cohort of patients with delusiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lähteenvuo, Markku, Taipale, Heidi, Tanskanen, Antti, Mittendorfer-Rutz, Ellenor, Tiihonen, Jari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234610/ http://dx.doi.org/10.1093/schbul/sbaa029.768

Ejemplares similares

S210. COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS FOR RISK OF ATTEMPTED OR COMPLETED SUICIDE AMONG PERSONS WITH SCHIZOPHRENIA
por: Taipale, Heidi, et al.
Publicado: (2020)

Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
por: Heikkinen, Milja, et al.
Publicado: (2022)

Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
por: Heikkinen, Milja, et al.
Publicado: (2021)

Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
por: Heikkinen, Milja, et al.
Publicado: (2022)

Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2020)

Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
por: Lintunen, Jonne, et al.
Publicado: (2021)

Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
por: Lieslehto, Johannes, et al.
Publicado: (2023)

Morbidity and mortality in schizophrenia with comorbid substance use disorders
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
por: Holm, Minna, et al.
Publicado: (2020)

Twenty‐year medication use trends in first‐episode bipolar disorder
por: Poranen, Juulia, et al.
Publicado: (2022)

Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
por: Lintunen, Jonne, et al.
Publicado: (2021)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
por: Puranen, Arto, et al.
Publicado: (2023)

Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study
por: Paljärvi, Tapio, et al.
Publicado: (2023)

Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2020)

Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2022)

T70. DUAL-PROCESS THEORY, CONFLICT PROCESSING, AND DELUSIONAL BELIEF
por: Bronstein, Michael, et al.
Publicado: (2020)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)

Patient factors associated with receipt of psychological and pharmacological treatments among individuals with common mental disorders in a Swedish primary care setting
por: Cullen, Alexis E., et al.
Publicado: (2023)

Morbidity and mortality in schizophrenia with comorbid substance use disorders in Finland and Sweden
por: Lähteenvuo, M., et al.
Publicado: (2021)

Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
por: Taipale, Heidi, et al.
Publicado: (2020)

T49. SOCIODEMOGRAPHIC AND LIFESTYLE FACTORS ASSOCIATED WITH GOOD PERFORMANCE IN PAIRED ASSOCIATES LEARNING TEST IN PATIENTS WITH SCHIZOPHRENIA
por: Taivalantti, Marjo, et al.
Publicado: (2020)

Initiation of antidepressant use among refugee and Swedish-born youth after diagnosis of a common mental disorder: findings from the REMAIN study
por: Taipale, Heidi, et al.
Publicado: (2020)

Labour market marginalisation in young adults diagnosed with attention-deficit hyperactivity disorder (ADHD): a population-based longitudinal cohort study in Sweden
por: Helgesson, Magnus, et al.
Publicado: (2023)

Risk Factors for Disability Pension among Young Adults Diagnosed with Attention-deficit Hyperactivity Disorder (ADHD) in Adulthood
por: Chen, Lingjing, et al.
Publicado: (2021)

Sustainable labour market participation among working young adults with diagnosed attention deficit/hyperactivity disorder (ADHD)
por: Helgesson, Magnus, et al.
Publicado: (2023)

The role of sociodemographic and clinical factors in the initiation and discontinuation of attention deficit hyperactivity disorder medication among young adults in Sweden
por: Gémes, Katalin, et al.
Publicado: (2023)

Occupational Branch and Labor Market Marginalization among Young Employees with Adult Onset of Attention Deficit Hyperactivity Disorder—A Population-Based Matched Cohort Study
por: Gémes, Katalin, et al.
Publicado: (2022)

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
por: Taipale, Heidi, et al.
Publicado: (2018)

Association of Socio-Demographic Factors, Sick-Leave and Health Care Patterns with the Risk of Being Granted a Disability Pension among Psychiatric Outpatients with Depression
por: Mittendorfer-Rutz, Ellenor, et al.
Publicado: (2014)

Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
por: Tiihonen, Miia, et al.
Publicado: (2016)

Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia: A Nationwide Analysis
por: Hamina, Aleksi, et al.
Publicado: (2020)

T43. PREDNISOLONE VERSUS PLACEBO AS AUGMENTATION THERAPY IN PSYCHOTIC DISORDERS
por: Lyliana, Nasib, et al.
Publicado: (2020)

Antipsychotic treatment patterns in refugees and their Swedish-born peers with first-episode non-affective psychosis: findings from the REMAIN study
por: Spaton Goppers, Julia, et al.
Publicado: (2023)

T178. MICROPIPETTE-GUIDED DRUG ADMINISTRATION (MDA) METHOD AS A NOVEL PHARMACOLOGICAL TREATMENT METHOD IN MICE: PRECLINICAL VALIDATION USING RISPERIDONE IN THE MATERNAL IMMUNE ACTIVATION MODEL OF NEURODEVELOPMENTAL DISORDERS
por: Scarborough, Joseph, et al.
Publicado: (2020)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

T129. PHARMACOLOGICAL INTERVENTIONS IN TRIALS OF PEOPLE WITH SCHIZOPHRENIA: A REGISTER-BASED CLASSIFICATION OF SEVENTY YEARS OF RESEARCH
por: Shokraneh, Farhad
Publicado: (2020)

Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
por: Sommer, Iris E, et al.
Publicado: (2022)

Trajectories of antidepressant medication use in individuals before and after being granted disability pension due to common mental disorders- a nationwide register-based study
por: Rahman, Syed, et al.
Publicado: (2018)

Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dmhe77la8l0lk97uq18bfab3pc